Analysts Question Biogen's Lupus Drug Litifilimab Ahead of Key Phase 3 Readouts
read at Endpoints ↗Neutral
Analysts pressed Biogen CEO Chris Viehbacher during a recent call, focusing on the company's late‑stage pipeline.
The discussion centered on litifilimab, Biogen’s experimental lupus therapy, with several Phase 3 trials slated to read out soon. These readouts are seen as pivotal to the CEO’s turnaround plan.
The intense questioning underscores heightened scrutiny, as the trial outcomes will shape Biogen’s strategic direction and investor sentiment.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Analysts press Biogen on lupus drug litifilimab ahead of pivotal readouts”
read at Endpoints ↗92 words · retrieved 27m ago
comments(0)
5-min edit window · permanent after that